Document is current

Article History

Received: 30 October 2023

Accepted: 18 March 2024

First Online: 3 April 2024

Change Date: 10 April 2024

Change Type: Correction

Change Details: Supplementary Figure 2 was cross linked incorrectly with Figure 2 and cross link was removed in this version.

Declarations

:

: TM, SY, AN, and RK are employees of Teijin Pharma Limited. RN has received honoraria from Astellas Pharma Inc., Astra Zeneca K.K., Boehringer Ingelheim Japan, Inc., Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Kowa Co., Ltd., Medtronic Japan Co., Ltd., Novo Nordisk Pharma Inc., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Taisho Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., and Abbott Japan LLC; research funding from Mitsubishi Electric Corp.; and subsidies or donations from Abbott Japan LLC, Boehringer Ingelheim Japan, Inc., Eli Lilly Japan K.K., Sumitomo Pharma Co., Ltd., Arkley Inc., and Taisho Pharmaceutical Co., Ltd.

: This article does not contain any studies with human or animal subjects performed by any of the authors.

: Because the data used in this study came from a large health insurance claims database and were fully anonymized, there was no need for informed consent from individual patients or approval from the Institutional Review Board (IRB).